# Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

> **NCT02162667** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 562 (actual)

## Conditions studied

- HER2-positive Carcinoma of Breast

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02162667
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-05-26
- **Final completion:** 2018-10
- **Target enrollment:** 562 (ACTUAL)
- **Last updated:** 2022-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162667, "Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02162667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*